Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [68Ga]Ga-DWJ155
Ga-DWJ155 · 1 trial · 2 indications
Imaging properties of FKL480 will be evaluated by assessing radiotracer uptake, identified via positron emission tomography (PET) scans. The SUVmean and SUVmax will be calculated and reported with summary statistics.
SUVr will be calculated by dividing the SUV of the lesions by the SUV of the different organs in order to identify the reference organ with the lowest uptake and the respective SUVr (i.e. using SUVmean or SUVmax).
| Arm | Type | Description |
|---|---|---|
| Advanced breast cancer | EXPERIMENTAL | Patients will receive FKL480 (\[68Ga\]Ga-DWJ155) |
| Advanced NSCLC | EXPERIMENTAL | Patients will receive FKL480 (\[68Ga\]Ga-DWJ155) |
| Name | Type | Description |
|---|---|---|
| [68Ga]Ga-DWJ155 | DRUG | Radioligand imaging agent |
Inclusion Criteria: * Age ≥ 18 years old * Patients with histologically or cytologically confirmed and documented HR+/HER2- advanced breast cancer (aBC), advanced defined as locoregionally advanced unresectable or metastatic, either untreated or currently receiving first line of systemic therapy OR...
Ga-DWJ155 is an investigational small molecule being studied for use in breast neoplasms. It is currently in Phase 1 clinical development for this indication. The drug is also being evaluated in patients with non-small-cell lung cancer as part of an ongoing clinical trial.
Ga-DWJ155 is a small molecule, but its specific molecular target has not been disclosed in available information. The drug is being studied in oncology, specifically for breast neoplasms and non-small-cell lung cancer, but its mechanism of action is not publicly detailed.
Ga-DWJ155 is being developed by Novartis AG, a multinational pharmaceutical company. Novartis is listed on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
Ga-DWJ155 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is actively recruiting participants to study the drug in patients with breast and lung cancers.
Ga-DWJ155 is being studied in a Phase 1 clinical trial with the identifier NCT07117214. This trial is titled 'A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers' and is currently recruiting participants in the Netherlands. The trial aims to enroll 36 patients.
Yes, Ga-DWJ155 is also known as [68Ga]Ga-DWJ155. The two names refer to the same investigational drug. The clinical trial NCT07117214 uses the name [68Ga]Ga-DWJ155 in its official title, while Ga-DWJ155 is the shorter form used in some contexts.